David G. Hicks

发表

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

Huina Zhang, Hani Katerji, B. Turner, 2022, Modern Pathology.

Detailed Morphologic Evaluation of Breast Papillary Lesions on Core Biopsy Is Critical for Accurate Classification and Clinical Management: The Experience of an Academic Institute.

David G. Hicks, K. Skinner, Xi Wang, 2021, Clinical breast cancer.

Vascular lesions of the breast: Essential pathologic features and diagnostic pitfalls

Huina Zhang, Hani Katerji, David G. Hicks, 2021, Human Pathology Reports.

Adenocarcinoma of the stomach following irradiation and chemotherapy for lymphoma in young patients

David G. Hicks, R. Brumback, J. Strauchen, 1984, Cancer.

HER2-low breast cancers: Current insights and future directions.

Huina Zhang, Hani Katerji, David G. Hicks, 2022, Seminars in diagnostic pathology.

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

Huina Zhang, Hani Katerji, B. Turner, 2022, Modern Pathology.

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

Tanja Cufer, Manfred Schmitt, Nadia Harbeck, 2009, Breast Cancer Research and Treatment.

The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations

Huina Zhang, B. Turner, David G. Hicks, 2023, Cancers.

Breast and Gynecologic Tumors

Huina Zhang, David G. Hicks, 2021, Practical Oncologic Molecular Pathology.

Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression

David G. Hicks, P. Tang, K. Skinner, 2014, Histopathology.

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing

Huina Zhang, Hani Katerji, B. Turner, 2023, Cancers.

Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach

Huina Zhang, Hani Katerji, B. Turner, 2021, Human Pathology Reports.

Open quiz solution: Case report 776

S. Totterman, David G. Hicks, M. J. Adams, 2004, Skeletal Radiology.

Granular Histiocytosis of Pelvic Lymph Nodes following Total Hip Arthroplasty. The Presence of Wear Debris, Cytokine Production, and Immunologically Activated Macrophages*

J. Puzas, R. O’Keefe, A. Judkins, 1996, The Journal of bone and joint surgery. American volume.

HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.

David G. Hicks, M. Cziraky, J. Barron, 2009, The oncologist.

p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?

B. Ring, P. Rothberg, David G. Hicks, 2016, Human pathology.

HER2 in uterine serous carcinoma: Current state and clinical perspectives.

Huina Zhang, Hani Katerji, B. Turner, 2023, American journal of clinical pathology.

Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward “precision” cancer therapy

B. Turner, David G. Hicks, D. Hicks, 2015, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

Extraosseous primary and recurrent giant cell tumors: transforming growth factor-beta1 and -beta2 expression may explain metaplastic bone formation.

J. O'Connell, R. O’Keefe, David G. Hicks, 1996, Human pathology.

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

M. Dowsett, D. Visscher, M. Hammond, 2010, Journal of oncology practice.

Treatment of multifocal lymphoma of bone with intensified Promace‐Cytabom chemotherapy and involved field radiotherapy

L. Constine, R. O’Keefe, David G. Hicks, 1998, American journal of hematology.

Diabetic mastopathy: a distinctive clinicopathologic entity.

V. Livolsi, David G. Hicks, J. Tomaszewski, 1992, Human pathology.

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

M. Dowsett, L. McShane, D. Allred, 2010, Journal of oncology practice.

Osteonecrosis of the temporomandibular joint: correlation of magnetic resonance imaging and histology.

P. Westesson, David G. Hicks, T. A. Larheim, 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

In ER Positive, HER2 Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX® Recurrence Score than HER2 Immunohistochemistry.

Huina Zhang, B. Turner, David G. Hicks, 2023, Laboratory investigation; a journal of technical methods and pathology.

HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category.

Huina Zhang, B. Turner, David G. Hicks, 2023, Human pathology.